Patents Assigned to Novira Therapeutics, INC.
  • Combinations and methods comprising a capsid assembly inhibitor
    Patent number: 11129834
    Abstract: The present disclosure is directed to capsid assembly inhibitor compositions and methods for use in the treatment of hepatitis B virus infection.
    Type: Grant
    Filed: August 15, 2019
    Date of Patent: September 28, 2021
    Assignees: Novira Therapeutics, Inc., Janssen Sciences Ireland Unlimited Company
    Inventors: George Hartman, Osvaldo Flores, Klaus Klumpp, Man Iu Lam, Jan Martin Berke
  • Oxadiazepinone derivatives and methods of treating hepatitis B infections
    Patent number: 10987359
    Abstract: Provided herein are compounds of formula (IA) and (III) useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: April 27, 2021
    Assignee: Novira Therapeutics, Inc.
    Inventors: Scott Kuduk, George D. Hartman
  • Diazepinone derivatives and their use in the treatment of hepatitis B infections
    Patent number: 10975077
    Abstract: Provided herein are compounds of formula (I) and (V) useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: April 13, 2021
    Assignee: Novira Therapeutics, Inc.
    Inventors: Scott Kuduk, George D. Hartman
  • Sulfide alkyl compounds for HBV treatment
    Patent number: 10710959
    Abstract: The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: July 14, 2020
    Assignee: NOVIRA THERAPEUTICS, INC.
    Inventors: Austin Chen, Yalda Bravo, Nicholas Stock, Bijan Pedram, Jason Jacintho, Ryan C. Clark
  • Combination therapy for treatment of HBV infections
    Patent number: 10632112
    Abstract: Provided herein is a combination therapy comprising a compound of Formula I and peginterferon alfa-2a, or another interferon analog. The combination therapy is useful for the treatment of HBV infection. Also provided herein are compositions comprising a compound of Formula I and peginterferon alfa-2a, or another interferon analog.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: April 28, 2020
    Assignee: NOVIRA THERAPEUTICS, INC.
    Inventor: George D. Hartman
  • Derivatives and methods of treating hepatitis B infections
    Patent number: 10556904
    Abstract: Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: February 11, 2020
    Assignee: NOVIRA THERAPEUTICS, INC.
    Inventors: George D. Hartman, Scott Kuduk
  • Derivatives and methods of treating hepatitis B infections
    Patent number: 10544141
    Abstract: Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: January 28, 2020
    Assignee: NOVIRA THERAPEUTICS, INC.
    Inventors: George D. Hartman, Scott Kuduk
  • Azocane and azonane derivatives and methods of treating hepatitis B infections
    Patent number: 10537580
    Abstract: Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: January 21, 2020
    Assignee: NOVIRA THERAPEUTICS, INC.
    Inventors: George D. Hartman, Scott Kuduk
  • Derivatives and methods of treating hepatitis B infections
    Patent number: 10538519
    Abstract: Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: January 21, 2020
    Assignee: NOVIRA THERAPEUTICS, INC.
    Inventors: George D. Hartman, Scott Kuduk
  • Combinations and methods comprising a capsid assembly inhibitor
    Patent number: 10441589
    Abstract: The present disclosure is directed to capsid assembly inhibitor compositions and methods for use in the treatment of hepatitis B virus infection.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: October 15, 2019
    Assignees: NOVIRA THERAPEUTICS, INC., Janssen Sciences Ireland Unlimited Company
    Inventors: George Hartman, Osvaldo Flores, Klaus Klumpp, Man Iu Lam, Jan Martin Berke
  • Pyridyl reverse sulfonamides for HBV treatment
    Patent number: 10428041
    Abstract: The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: October 1, 2019
    Assignee: NOVIRA THERAPEUTICS, INC.
    Inventors: Ryan C. Clark, Yen Truong, Nicholas Stock, Jason Jacintho
  • Azepane derivatives and methods of treating hepatitis B infections
    Patent number: 10392349
    Abstract: Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: August 27, 2019
    Assignee: NOVIRA THERAPEUTICS, INC.
    Inventors: George D. Hartman, Scott Kuduk
  • Azepane derivatives and methods of treating hepatitis B infections
    Patent number: 10364228
    Abstract: Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: July 30, 2019
    Assignee: NOVIRA THERAPEUTICS, INC.
    Inventor: George D. Hartman
  • Combination therapy for treatment of HBV infections
    Patent number: 10213420
    Abstract: Provided herein is a combination therapy comprising a compound of Formula I and peginterferon alfa-2a, or another interferon analog. The combination therapy is useful for the treatment of HBV infection. Also provided herein are compositions comprising a compound of Formula I and peginterferon alfa-2a, or another interferon analog.
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: February 26, 2019
    Assignee: NOVIRA THERAPEUTICS, INC.
    Inventor: George D. Hartman
  • Sulfide alkyl compounds for HBV treatment
    Patent number: 10196351
    Abstract: The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: February 5, 2019
    Assignee: NOVIRA THERAPEUTICS, INC.
    Inventors: Austin Chen, Yalda Bravo, Nicholas Stock, Bijan Pedram, Jason Jacintho, Ryan C. Clark
  • Hepatitis B antiviral agents
    Patent number: 10196376
    Abstract: The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: February 5, 2019
    Assignee: NOVIRA THERAPEUTICS, INC.
    Inventors: George D. Hartman, Osvaldo A. Flores
  • Derivatives and methods of treating hepatitis B infections
    Patent number: 10189835
    Abstract: Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: January 29, 2019
    Assignee: NOVIRA THERAPEUTICS, INC.
    Inventors: George D. Hartman, Scott Kuduk
  • Pyridyl reverse sulfonamides for HBV treatment
    Patent number: 10160742
    Abstract: The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: December 25, 2018
    Assignee: NOVIRA THERAPEUTICS, INC.
    Inventors: Ryan C. Clark, Yen Truong, Nicholas Stock, Jason Jacintho
  • Derivatives and methods of treating hepatitis B infections
    Patent number: 10093669
    Abstract: Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: October 9, 2018
    Assignee: NOVIRA THERAPEUTICS, INC.
    Inventors: George D. Hartman, Scott Kuduk
  • Crystalline forms of a hepatitis B antiviral agent
    Patent number: 10077239
    Abstract: This disclosure provides crystalline forms of a hepatitis B antiviral agent, and methods of making and using these forms.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: September 18, 2018
    Assignee: NOVIRA THERAPEUTICS, INC.
    Inventor: George D. Hartman